Clinical Trial

QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer

Name: QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer — clinical trial record (NCT07636226)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2/3

View on ClinicalTrials.gov →

Summary

This is a multicenter, open-label, randomized controlled phase II/III study evaluating the efficacy and safety of QL1706 in combination with anlotinib as later-line treatment in patients with advanced lung cancer.

Trial Details

NCT Number	NCT07636226
Lead Sponsor	Sun Yat-sen University
Conditions	Small Cell Lung Cancer
Enrollment	120 participants
Start Date	2026-07-30
Primary Completion	2028-12-30 (estimated)
Study Completion	2029-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-09